 |
|
Elevated levels of soluble ST2 but not galectin-3 are associated with increased risk of mortality in hemodialysis patients
Ae Jin Kim, Han Ro, Hyunsook Kim, Kwang-Pil Ko, Jae Hyun Chang, Hyun Hee Lee, Wookyung Chung, Ji Yong Jung
Kidney Res Clin Pract. 2021;40(1):109-119. Published online 2021 Mar 5 DOI: https://doi.org/10.23876/j.krcp.20.133
|
|
Citations to this article as recorded by
 Association of serum galectin-3 levels with mortality and cardiovascular disease outcomes in hemodialysis patients: a systematic review and dose–response meta-analysis
Ioannis Bellos, Smaragdi Marinaki, Pagona Lagiou, Vassiliki Benetou
International Urology and Nephrology.2024; 56(8): 2755. CrossRef Circulating galectin-3 level association with cardiovascular risk factors during peritoneal dialysis
Xuerui Yang, Jun Yang, Youjia Zeng, Ling Peng, Xingzheng Liu, Jinying Mo, Taifen Wang, Yutong Yao, Yihou Zheng, Gaofeng Song
Clinical and Experimental Nephrology.2024; 28(9): 925. CrossRef Association of soluble suppression of tumorigenicity 2 with mortality and adverse outcomes in chronic kidney disease: a systematic review and meta-analysis
Ioannis Bellos, Smaragdi Marinaki, Pagona Lagiou, Vassiliki Benetou
Clinical and Experimental Nephrology.2024; 28(10): 988. CrossRef Fasting blood glucose and the risk of all-cause mortality in patients with diabetes mellitus undergoing hemodialysis
Soo-Young Yoon, Jin Sug Kim, Gang Jee Ko, Yun Jin Choi, Ju Young Moon, Kyunghwan Jeong, Hyeon Seok Hwang
Kidney Research and Clinical Practice.2024; 43(5): 680. CrossRef Emotional and cognitive changes in chronic kidney disease
Duk-Soo Kim, Seong-Wook Kim, Hyo-Wook Gil
The Korean Journal of Internal Medicine.2022; 37(3): 489. CrossRef
|